Feature | Ventricular Assist Devices (VAD) | June 04, 2018

Medtronic HeartWare HVAD System Recalled Due to Unintended Disconnection of Power Source

FDA Class I recall includes all 204,017 HVADs made since 2006

The Medtronic HeartWare Ventricular Assist Devices (HVAD) has a Class I FDA recall.
Image of the device showing the internal HVAD pump, which is connected to the external controller by a driveline cable through the skin. The controller is connected externally to the monitor, the AC adapter, and the battery.

Image of the device showing the internal HVAD pump, which is connected to the external controller by a driveline cable through the skin. The controller is connected externally to the monitor, the AC adapter, and the battery.

June 4, 2018 — The U.S. Food and Drug Administration said Medtronic initiated a Class 1 recall all 204,017 of its HeartWare Ventricular Assist Devices (HVAD) produced between March 2006 to May 2018. 

Medtronic said there is a possibility for an interruption to occur in the electrical connection between the system’s power source (battery, AC adapter, or DC adapter) and the HVAD controller. This interruption to the electrical connection, which occurs when the power source is still physically connected, is caused by oxidation on the connecting surfaces between the power source connector and the controller’s power source socket. The interruptions to the electrical connection could cause unintended intermittent electrical disconnection, which could result in a pump stop. A pump stop could cause patient harm such as exacerbation of heart failure symptoms, or symptoms such as mild weakness, dizziness, anxiety, nausea, loss of consciousness, or death.

The HeartWare HVAD is indicated for use as a bridge to cardiac transplantation in patients who are at risk of death from end-stage left ventricular heart failure. It functions as a pump that helps the heart deliver blood to the rest of the body. The HeartWare system is designed for in-hospital and out-of-hospital settings, including transportation via fixed wing aircraft or helicopter. These indications have been expanded to include HVAD use for myocardial recovery, or as destination therapy in patients for whom subsequent transplantation is not planned.

Medtronic said the recall encompasses all HVAD systems manufacturing and distribution between March 2006 to May 2018, which includes 204,017 devices in the United States. 

Medtronic sent a letter on May 2, 2018 advising hospitals and physicians to:
   • Reinforce the importance of always ensuring two power sources are connected at all times
   • Reinforce best practice guidance for managing power sources when going to sleep and awakening
   • Instruct patients to report any persistent, unexpected audible tones to the VAD team for additional instructions

The FDA released a public statement about the HVAD recall June 4. 

Customers who need additional information about this recall can contact Medtronic Customer Service at (877) 367-4823

This is the second major LVAD recall in the past month. In May, Abbott has initiated a Class I recall of more than 4,000 HeartMate 3 Left Ventricular Assist systems due to a malfunction in the device’s outflow graft assembly. The company said the malfunction may cause the outflow graft to twist and close up (occlusion) over time. Occlusion of the outflow graft can reduce or stop pump flow and set off a persistent low flow alarm in the system. A reduction in pump can lead to serious adverse events such as blood clots and death. 

Related Content:

FDA Recall Database Document for HVAD Recall

Medtronic HeartWare HVAD System Approved for Destination Therapy

Abbott Recalls the HeartMate 3 Left Ventricular Assist System

 

Related Content

Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Antithrombin Drug Ineffective in Heart Failure With Sinus Rhythm and Coronary Disease
News | Heart Failure | September 07, 2018
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction...
Tafamidis Improves Survival in Rare Heart Condition
News | Heart Failure | September 06, 2018
Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart condition called...
New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init